Articles

Podcasts

Videos

Clinical

A recent study in the United Kingdom suggests that more research into the possible benefits of antiviral drug tecovirimat for treating monkeypox may be warranted after showing positive results in one patient.

Antiviral Drug Tecovirimat May Shorten Duration of Monkeypox Illness

Community transmission of monkeypox outside traditional endemic regions of the virus prompts calls for increased vigilance.

Physicians Called on to Recognize and Report Monkeypox

At a media briefing this morning, Infectious Diseases Society of America (IDSA) experts discussed the worldwide 600 confirmed cases of monkeypox.

IDSA Explains Current State of Monkeypox in the US

Verrica received a Complete Response Letter from the FDA regarding their New Drug Application for the topical molluscum contagiosum treatment, VP-102. 

FDA Cites Manufacturing Deficiencies in Second Complete Response Letter for Verrica’s VP-102

Shortages of health care workers and an increase in COVID-19 cases has put a severe strain on the health care system. Thus, the opportunity to reduce the hospitalizations for other conditions and expand outpatient treatment opportunities should be welcomed. 

In These COVID 19 Times, Can We Reduce Hospitalizations Due to Skin Infections?

A case series observation study found a slightly higher risk of Guillain-Barre syndrome among Medicare beneficiaries within 42 days after receiving the recombinant zoster vaccine Shingrix, but no changes are needed to guidance recommending the vaccine, investigators said.

Risk of Guillain-Barre Syndrome Higher with Recombinant Zoster Vaccine Shingrix

This approval of the non-live, recombinant sub-unit adjuvanted vaccine, Shingrix, is for the prevention of shingles in adults aged 18 years and older with increased risk of immunodeficiency or immunosuppression.

FDA Approves Vaccine to Prevent Shingles in Immunocompromised Adults

This therapy becomes the first single-dose infusion to treat acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth.

FDA Approves Dalbavancin

CDC and WHO Data shows a 50% increase worldwide from 3 years ago.

Measles Deaths Increase Significantly

“The compound appears to be safe and well-tolerated, [and we observed] excellent efficacy based on a very small sample size,” Peter G. Pappas, MD, said.

SKIN & SOFT TISSUE DISEASES

Latest News